AMGN Share Price

Open 154.71 Change Price %
High 155.35 1 Day 0.87 0.57
Low 153.82 1 Week -1.45 -0.93
Close 154.67 1 Month 8.50 5.82
Volume 3007304 1 Year 1.89 1.24
52 Week High 176.85
52 Week Low 133.64
AMGN Important Levels
Resistance 2 156.09
Resistance 1 155.50
Pivot 154.61
Support 1 153.84
Support 2 153.25
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%

Amgen Inc. (NASDAQ: AMGN)

AMGN Technical Analysis 2
As on 20th Jan 2017 AMGN Share Price closed @ 154.67 and we RECOMMEND Sell for LONG-TERM with Stoploss of 156.72 & Strong Buy for SHORT-TERM with Stoploss of 147.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMGN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AMGN Other Details
Segment EQ
Market Capital 67280416768.00
Sector Healthcare
Industry Biotechnology
Offical website
AMGN Address
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone: 805-447-1000
Fax: 805-447-1010
AMGN Latest News
BancorpSouth Inc Boosts Position in Amgen Inc. (AMGN)   Sports Perspectives   - 20th Jan 17
Why the Amgen, Inc. (AMGN) Patent Case Is So Important   - 18th Jan 17
Amgen Inc. v. Sandoz Inc.   Lexology (registration)   - 18th Jan 17
Shares Reports Bring Up To Date: Amgen Inc. (NASDAQ:AMGN) , Surgical Care ...   WsNews 4investors   - 18th Jan 17
Intermede Investment Partners Ltd Buys Wells Fargo & Co, Facebook Inc, Amgen ...   Nasdaq   - 18th Jan 17
Better Buy: Amgen Inc. vs. Celgene Corporation   Motley Fool   - 17th Jan 17
Should You Buy Amgen Inc. (AMGN) Stock? 3 Pros, 3 Cons   - 11th Jan 17
Amgen Should Drop At Least 10% To 15%   Seeking Alpha   - 10th Jan 17
Amgen Inc. (AMGN) Is Surging After Court Upholds Patent For Repatha   Nasdaq   - 06th Jan 17
Amgen Wins Ban on Sanofi's Praluent Cholesterol Drug Sales   Bloomberg   - 06th Jan 17
Interactive Technical Analysis Chart Amgen Inc. ( AMGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Amgen Inc.
AMGN Business Profile
Amgen Inc., incorporated on October 31, 1986, is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In June 12, 2012, the Company acquired substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN). In March 7, 2012, the Company acquired Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications. The Company’s principal products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, XGEVA and Prolia. Its principal products are Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection); Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in inflammatory diseases; Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab), two products that contain the same active ingredient but which are approved for different indications, patient populations, doses and frequencies of administration. In addition to its marketed products, the Company has various product candidates in mid-to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience.